for investors

Investors

corporate profile
Ovid Therapeutics Inc. is a New York-based biopharmaceutical company using its BoldMedicine® approach to develop medicines that transform the lives of patients with rare neurological disorders. Ovid has a broad pipeline of potential first-in-class medicines. The company’s most advanced investigational medicine, OV101 (gaboxadol), is currently in clinical development for the treatment of Angelman syndrome and Fragile X syndrome. Ovid is also developing OV935 (soticlestat) in collaboration with Takeda Pharmaceutical Company Limited for the potential treatment of rare developmental and epileptic encephalopathies (DEE).
stock
snapshot
Additional stock info »
12.4.2020 | 11:52 AM EST
Copyright West LLC. Minimum 15 minutes delayed.
Press Releases
Dec 01, 2020
Ovid Therapeutics Announces Phase 3 NEPTUNE Clinical Trial of OV101 for the Treatment of Angelman Syndrome Did Not Meet Primary Endpoint
Nov 23, 2020
Ovid Therapeutics to Present at the American Epilepsy Society (AES) 2020 Virtual Congress
Nov 12, 2020
Ovid Therapeutics Reports Third Quarter 2020 Financial Results and Provides Corporate Update
View all news »
Events & Presentations
Oct 22, 2020 1:00 PM EDT
Ovid Therapeutics Hosts Educational Webinar on Angelman Syndrome and OV101 Development Program
Oct 12 - Oct 23, 2020
Ovid Therapeutics Inc at Child Neurology Society/International Child Neurology Association (CNS/ICNA) 2020 Virtual Congress
Sep 17, 2020 2:00 PM EDT
Ovid Therapeutics Inc at 2020 Cantor Fitzgerald Virtual Global Healthcare Conference
View all events and presentations »
Latest Corporate Presentation Get the Ovid primer— download our latest corporate presentation for investors.
Explore the Ovid Pipeline The Ovid pipeline includes several candidates that would potentially be the first to make a meaningful impact in the lives of individuals with rare neurological conditions. View our pipeline »
Get Investor Updates Have the latest on the BOLD happenings at Ovid, from clinical trial endpoint and data announcements to corporate news, sent right to your inbox. Sign up now »
latest updates